BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rajamanickam S, Kaur M, Velmurugan B, Singh RP, Agarwal R. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res 2009;26:2558-67. [PMID: 19779968 DOI: 10.1007/s11095-009-9968-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med 2022;27:2515690X211068826. [PMID: 35018864 DOI: 10.1177/2515690X211068826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Saxena A, Tammali R, Ramana KV, Srivastava SK. Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice. Curr Cancer Drug Targets 2018;18:905-11. [PMID: 28786349 DOI: 10.2174/1568009617666170808105633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sun T, Cheung KSC, Liu Z, Leung F, Lu WW. Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma. Mol Carcinog 2018;57:262-71. [DOI: 10.1002/mc.22753] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
4 Tsaroucha AK, Valsami G, Kostomitsopoulos N, Lambropoulou M, Anagnostopoulos C, Christodoulou E, Falidas E, Betsou A, Pitiakoudis M, Simopoulos CE. Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury. Journal of Investigative Surgery 2018;31:491-502. [DOI: 10.1080/08941939.2017.1360416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
5 Williams C, DiLeo A, Niv Y, Gustafsson JÅ. Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett 2016;372:48-56. [PMID: 26708506 DOI: 10.1016/j.canlet.2015.12.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
6 Raina K, Kumar S, Dhar D, Agarwal R. Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res 2016;30:452-65. [PMID: 27476880 DOI: 10.7555/JBR.30.20150111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
7 Abdollahi P, Ebrahimi M, Motamed N, Samani FS. Silibinin affects tumor cell growth because of reduction of stemness properties and induction of apoptosis in 2D and 3D models of MDA-MB-468. Anticancer Drugs 2015;26:487-97. [PMID: 25603020 DOI: 10.1097/CAD.0000000000000205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
8 Wang X, Song ZJ, He X, Zhang RQ, Zhang CF, Li F, Wang CZ, Yuan CS. Antitumor and immunomodulatory activity of genkwanin on colorectal cancer in the APC(Min/+) mice. Int Immunopharmacol 2015;29:701-7. [PMID: 26388189 DOI: 10.1016/j.intimp.2015.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
9 Christodoulou E, Kechagia IA, Tzimas S, Balafas E, Kostomitsopoulos N, Archontaki H, Dokoumetzidis A, Valsami G. Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product. Int J Pharm 2015;493:366-73. [PMID: 26222744 DOI: 10.1016/j.ijpharm.2015.07.060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
10 Kumar S, Raina K, Agarwal C, Agarwal R. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget 2014;5:4972-89. [PMID: 24970802 DOI: 10.18632/oncotarget.2068] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
11 Kellici TF, Ntountaniotis D, Leonis G, Chatziathanasiadou M, Chatzikonstantinou AV, Becker-baldus J, Glaubitz C, Tzakos AG, Viras K, Chatzigeorgiou P, Tzimas S, Kefala E, Valsami G, Archontaki H, Papadopoulos MG, Mavromoustakos T. Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-β-cyclodextrin through Biophysical Techniques and Computational Methods. Mol Pharmaceutics 2015;12:954-65. [DOI: 10.1021/mp5008053] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
12 Saxena A, Shoeb M, Tammali R, Ramana KV, Srivastava SK. Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Cancer Lett 2014;355:141-7. [PMID: 25218594 DOI: 10.1016/j.canlet.2014.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
13 Raina K, Agarwal R. Promise and potential of silibinin in colorectal cancer management: what patterns can be seen? Future Oncol 2013;9:759-61. [PMID: 23718291 DOI: 10.2217/fon.13.51] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Derry MM, Raina K, Agarwal C, Agarwal R. Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol 2013;3:119. [PMID: 23675573 DOI: 10.3389/fonc.2013.00119] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
15 Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013;15:707-16. [PMID: 23588585 DOI: 10.1208/s12248-013-9486-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
16 Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013;9:697-713. [PMID: 23445752 DOI: 10.4161/auto.23960] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
17 Kumar M, Nagpal R, Verma V, Kumar A, Kaur N, Hemalatha R, Gautam SK, Singh B. Probiotic metabolites as epigenetic targets in the prevention of colon cancer. Nutr Rev. 2013;71:23-34. [PMID: 23282249 DOI: 10.1111/j.1753-4887.2012.00542.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
18 Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal 2012;24:2291-6. [PMID: 22820499 DOI: 10.1016/j.cellsig.2012.07.009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 7.2] [Reference Citation Analysis]
19 Sangeetha N, Viswanathan P, Balasubramanian T, Nalini N. Colon cancer chemopreventive efficacy of silibinin through perturbation of xenobiotic metabolizing enzymes in experimental rats. European Journal of Pharmacology 2012;674:430-8. [DOI: 10.1016/j.ejphar.2011.11.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
20 Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog 2013;52:195-206. [PMID: 22086675 DOI: 10.1002/mc.21843] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
21 Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM. Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 2011;13:131-44. [PMID: 21403839 DOI: 10.1593/neo.101172] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
22 Sung B, Prasad S, Yadav VR, Lavasanifar A, Aggarwal BB. Cancer and diet: How are they related? Free Radic Res 2011;45:864-79. [PMID: 21651450 DOI: 10.3109/10715762.2011.582869] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
23 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010;29:447-63. [PMID: 20714788 DOI: 10.1007/s10555-010-9237-0] [Cited by in Crossref: 149] [Cited by in F6Publishing: 129] [Article Influence: 12.4] [Reference Citation Analysis]
24 Pan MH, Lai CS, Wu JC, Ho CT. Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res. 2011;55:32-45. [PMID: 21207511 DOI: 10.1002/mnfr.201000412] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 9.4] [Reference Citation Analysis]
25 Ai W, Zhang Y, Tang QZ, Yan L, Bian ZY, Liu C, Huang H, Bai X, Yin L, Li H. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 2010;110:1111-22. [PMID: 20564207 DOI: 10.1002/jcb.22623] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
26 Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res 2010;27:2085-97. [PMID: 20628792 DOI: 10.1007/s11095-010-0207-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
27 Sangeetha N, Aranganathan S, Panneerselvam J, Shanthi P, Rama G, Nalini N. Oral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model. Eur J Pharmacol 2010;643:93-100. [PMID: 20537993 DOI: 10.1016/j.ejphar.2010.05.060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]